In Depth 26 Sep 2024
The radiopharmaceutical revolution: From diagnosis to treatment, oncology and beyond
Delve into the world of radiopharmaceuticals: explore their mechanisms, promising candidates, and the key players driving innovation.
radiotherapy
- Latest Posts
Podcast 23 Aug 2024
New German biotech spins out to develop radiotherapeutics
While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company
Podcast 5 Jul 2024
The radiotherapeutics boom
The field of radiotherapeutics is a hot topic currently. Listen to our conversation with three experts in the field.
News and Trends 13 Jun 2023
ITM follows €255M investment round by opening new facility
After a recent funding announcement, Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, has opened its new production facility for therapeutic radionuclides in Neufahrn near Munich, Germany. ITM’s new facility is the world’s largest production site of lutetium-177, an innovative medical isotope used in targeted cancer therapies. Due to its medical properties, lutetium-177 has […]
News and Trends 17 Mar 2023
How cancer cells repair DNA damage from radiotherapy
A team of scientists led by Kei-ichi Takata from the Center for Genomic Integrity (CGI) within the Institute for Basic Science (IBS) in South Korea, has discovered a new type of DNA repair mechanism that cancer cells use to recover from next-generation cancer radiation therapy. Ionizing radiation (IR) therapy is frequently used in the treatment […]
News and Trends 20 Jan 2023
New drug could replace current standard for treating brain cancer
Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation chemotherapy combined with temozolomide is the standard line of treatment, GBM cells surviving radiotherapy contribute to tumor progression and recurrence even more aggressively. Researchers have now unveiled the mechanism of radioresistance in glioblastoma cells, identifying therapeutic targets to overcome radioresistance. […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 9 Dec 2022
Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients
Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Siddhartha Mukherjee, assistant professor of Medicine at Columbia University Medical Center in the Department of Medicine and Division […]
News and Trends 6 Dec 2022
Startup Graegis developing therapies for radiation side-effects
Graegis Pharmaceuticals, a startup developing new therapies aimed at preventing the side effects of radiotherapies, is set to complete the regulatory nonclinical package allowing entry in clinical trials. The company, founded in the last quarter of 2021, spent the first year of operations running critical experiments on the new therapies, which will target radiation side […]
News and Trends 10 Nov 2022
New radiopharmaceutical shrinks prostate cancer tumors
Researchers in Japan and Germany say a radiopharmaceutical treatment targeting a prostate-specific membrane antigen effectively shrinks prostate tumors in mice. The team reported the anti-cancer treatment zeroes in on tumor cells with ‘laser precision.’ Recent developments, such as targeted α-therapies as a type of theranostics, are trying to tackle cancer. Theranostics is a one-two punch […]
News and Trends 22 Sep 2022
Study data for glioblastoma treatment confirms safety and tolerability profile
The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) administered with external beam radiation therapy (EBRT) and the primary objective was to evaluate and test the safety and tolerability profile of the intravenous therapy […]
ADVERTISEMENT